Affiliate links: as an Amazon Associate and through other programs, we earn from qualifying purchases, at no extra cost to you. Learn more.
Quick answer: SAMe is a compound the body makes that is sold as a supplement for depression, joint pain and liver health. For depression, the latest Cochrane review found only low or very low quality evidence, and for osteoarthritis the effect on pain was small and uncertain. Do not combine it with antidepressants or use it if you have bipolar disorder unless your doctor supervises it.
In This Article
What SAMe Is
S-adenosyl-L-methionine, or SAMe, is a chemical made in the body from methionine, an amino acid found in food, and it helps regulate key functions in cells. In Europe it is also called ademetionine, and in the United States it is sold as a dietary supplement (NCCIH).
Get our free supplement cheat sheet.
One page: typical doses, timing and upper limits for ten well-studied supplements. No upsell.
🔒 No spam. Unsubscribe anytime. We send 1-2 emails/month max.
Researchers studied it for depression, osteoarthritis and liver disease because abnormal SAMe levels have been reported in depression and liver disease. Some studies gave SAMe by injection, which may not have the same effects as a supplement taken by mouth (NCCIH).
SAMe for Depression: What the Trials Show
The latest Cochrane review, from 2016, included 8 trials with 934 adults. When SAMe was the only treatment, there was no strong evidence of a difference from placebo, based on 2 studies with 142 people and very low quality evidence. SAMe and the older antidepressant imipramine gave similar results, but that evidence was of low quality (Galizia et al., 2016).
Added to an SSRI antidepressant, SAMe did better than placebo in one trial of 73 people, which the review rated as low quality evidence. The authors concluded that, without high-quality evidence, no firm conclusions can be drawn (Galizia et al., 2016).
- The add-on trial: 73 people who had not responded to a serotonin reuptake inhibitor antidepressant kept taking it and added SAMe, with a target of 800 mg twice a day, or a placebo for 6 weeks. Response rates were 36.1% with SAMe and 17.6% with placebo (Papakostas et al., 2010).
- SAMe against a modern antidepressant: in a 12-week trial in 189 adults, SAMe at 1,600 to 3,200 mg a day, escitalopram and placebo all improved depression scores by 5 to 6 points, with no significant difference between them. The NIH funded the trial, and a supplement company supplied the SAMe (Mischoulon et al., 2014).
- All trials pooled: a 2024 meta-analysis of 14 trials with 1,522 people, using 200 to 3,200 mg a day for 2 to 12 weeks, found no significant difference against placebo, imipramine or escitalopram, and urged caution because the trials were few and the doses varied widely (Peng et al., 2024).
NCCIH counts at least 40 studies of SAMe for depression; many reported benefits, but most were short, small and not of the highest quality (NCCIH). Depression is a medical condition: see a doctor or mental health professional, and do not stop prescribed medicine on your own. In the US, you can call or text 988 at any time to reach the 988 Suicide and Crisis Lifeline (988 Lifeline).
SAMe for Osteoarthritis
A 2009 Cochrane review found 4 placebo-controlled trials with 656 people with knee or hip osteoarthritis. Pain scores were 0.4 cm lower on a 10 cm scale with SAMe, a small difference that was not statistically significant, and function did not differ. The trials were small and of poor quality, and the authors advised against routine use (Rutjes et al., 2009).
Comparisons with pain relievers look better for SAMe. A 2002 meta-analysis of 11 studies found it about as effective as NSAIDs for pain and function, with fewer side effects, although the comparison with placebo rested on only 2 studies (Soeken et al., 2002). In a 16-week crossover trial in 61 adults with knee osteoarthritis, 1,200 mg of SAMe a day relieved pain more slowly than celecoxib in the first month but matched it by the second month; a supplement company provided the SAMe (Najm et al., 2004).
NCCIH sums up the osteoarthritis research as mixed: SAMe looked similar to NSAIDs in head-to-head studies, but the smaller number of placebo-controlled studies did not consistently show a benefit (NCCIH).
Liver Disease, Other Uses and Doses Studied
Low SAMe levels have been linked with liver disease, and animal studies looked promising, but whether SAMe helps liver disease in people has not been established (NCCIH). A Cochrane review of SAMe for alcohol-related liver disease was withdrawn in 2015 because it had not been updated since its 2008 edition (Rambaldi and Gluud, 2015). If you have liver disease, let your liver specialist decide on any supplement.
SAMe has also been studied for fibromyalgia, migraine, Alzheimer’s disease and ADHD, without enough evidence to reach conclusions, and a trial for quitting smoking found no benefit (NCCIH).
| Use studied | Doses tested | What was found |
|---|---|---|
| Depression, added to an SSRI | 800 mg twice a day for 6 weeks (Papakostas et al., 2010) | More responders than placebo in 73 people |
| Depression, SAMe alone | 1,600 to 3,200 mg a day for 12 weeks (Mischoulon et al., 2014) | No better than placebo in 189 adults |
| Knee osteoarthritis | 1,200 mg a day for 16 weeks (Najm et al., 2004) | Similar to celecoxib after 2 months in 61 adults |
| All depression trials | 200 to 3,200 mg a day for 2 to 12 weeks (Peng et al., 2024) | No significant difference from comparators |
There is no established dose. The amounts above are what studies used, not recommendations.
Side Effects and Interactions
Side effects are uncommon and usually minor, such as nausea or an upset stomach (NCCIH). In the 12-week depression trial, the most common side effects with SAMe were stomach discomfort (19%) and diarrhea (20%) (Mischoulon et al., 2014).
- Bipolar disorder: SAMe may worsen mania (NCCIH). The Cochrane review recorded 2 cases of mania or hypomania among 441 people taking SAMe (Galizia et al., 2016).
- Antidepressants and other serotonin products: SAMe might interact with antidepressants, L-tryptophan and St. John’s wort (NCCIH). Serotonin syndrome most often happens when two or more medicines or drugs that affect serotonin are taken together (MedlinePlus).
- Parkinson’s disease: SAMe may reduce the effect of levodopa (NCCIH).
- A weakened immune system: there is a theoretical concern that SAMe could help the microorganism Pneumocystis grow and cause infection in people who are immunocompromised, such as people with HIV (NCCIH).
- Pregnancy: SAMe has been used for a liver condition during pregnancy (cholestasis), but its safety in pregnancy has not been established (NCCIH).
- Long-term use: data are limited, although one 2-year study in alcohol-related liver disease reported no serious side effects (NCCIH).
Common Questions About SAMe
Does SAMe work for depression?
The evidence is weak. The latest Cochrane review found no strong evidence that SAMe on its own beats placebo and rated the evidence as low or very low quality (Galizia et al., 2016).
Can I take SAMe with my antidepressant?
Only with your doctor’s approval and supervision. SAMe might interact with antidepressants (NCCIH), and serotonin syndrome most often happens when two or more medicines or drugs that affect serotonin are taken together (MedlinePlus).
Is SAMe safe if I have bipolar disorder?
Not without a doctor’s care. NCCIH warns that SAMe may worsen symptoms of mania (NCCIH).
Does SAMe help knee pain?
Maybe a little. A Cochrane review found a small drop in pain versus placebo that was not statistically significant, in poor-quality trials (Rutjes et al., 2009), while older comparisons with NSAIDs found similar relief (Soeken et al., 2002).
How much SAMe did studies use?
Depression trials used 200 to 3,200 mg a day (Peng et al., 2024), and one knee osteoarthritis trial used 1,200 mg a day (Najm et al., 2004). These are study doses, not a recommended dose.
The Bottom Line
SAMe has decades of research, but most trials are small, short and of low quality. For depression, one add-on trial was positive (Papakostas et al., 2010), yet the best review found no clear benefit over placebo (Galizia et al., 2016). For osteoarthritis, any effect on pain looks small (Rutjes et al., 2009).
The safety issues are real: mania in bipolar disorder, interactions with antidepressants and levodopa, and unknown safety in pregnancy (NCCIH). Raise it with your doctor; it is not a substitute for medical care.
Scientific References
- Galizia et al., 2016. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev.
- Papakostas et al., 2010. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry.
- Mischoulon et al., 2014. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry.
- Peng et al., 2024. S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis. Gen Hosp Psychiatry.
- Rutjes et al., 2009. S-Adenosylmethionine for osteoarthritis of the knee or hip. Cochrane Database Syst Rev.
- Soeken et al., 2002. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract.
- Najm et al., 2004. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord.
- Rambaldi and Gluud, 2015. WITHDRAWN: S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev.
- National Center for Complementary and Integrative Health (NCCIH): S-Adenosyl-L-Methionine (SAMe): In Depth (updated January 2017).
- MedlinePlus (National Library of Medicine): Serotonin syndrome (updated April 13, 2026).
- 988 Suicide and Crisis Lifeline: Get Help.



